HK1202922A1 - Biomarkers for cancers responsive to modulators of hec1 activity hec1 - Google Patents

Biomarkers for cancers responsive to modulators of hec1 activity hec1

Info

Publication number
HK1202922A1
HK1202922A1 HK15103327.1A HK15103327A HK1202922A1 HK 1202922 A1 HK1202922 A1 HK 1202922A1 HK 15103327 A HK15103327 A HK 15103327A HK 1202922 A1 HK1202922 A1 HK 1202922A1
Authority
HK
Hong Kong
Prior art keywords
hec1
biomarkers
modulators
activity
cancers responsive
Prior art date
Application number
HK15103327.1A
Other languages
English (en)
Chinese (zh)
Inventor
Yu-Ling Huang
Johnson Lau
Original Assignee
Taivex Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taivex Therapeutics Corp filed Critical Taivex Therapeutics Corp
Publication of HK1202922A1 publication Critical patent/HK1202922A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
HK15103327.1A 2011-11-21 2015-04-22 Biomarkers for cancers responsive to modulators of hec1 activity hec1 HK1202922A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161562177P 2011-11-21 2011-11-21
PCT/US2012/065923 WO2013078145A1 (en) 2011-11-21 2012-11-19 Biomarkers for cancers responsive to modulators of hec1 activity

Publications (1)

Publication Number Publication Date
HK1202922A1 true HK1202922A1 (en) 2015-10-09

Family

ID=48470233

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15103327.1A HK1202922A1 (en) 2011-11-21 2015-04-22 Biomarkers for cancers responsive to modulators of hec1 activity hec1

Country Status (10)

Country Link
US (1) US9976183B2 (de)
EP (1) EP2783217B1 (de)
JP (1) JP6099662B2 (de)
CN (1) CN104395752B (de)
ES (1) ES2736999T3 (de)
HK (1) HK1202922A1 (de)
MX (1) MX2014006088A (de)
SG (2) SG11201402143YA (de)
TW (3) TWI641386B (de)
WO (1) WO2013078145A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2793311C (en) 2010-03-17 2019-01-15 Taivex Therapeutics Inc. Modulators of hec1 activity and methods therefor
US11071736B2 (en) * 2011-11-21 2021-07-27 Taivex Therapeutics Corporation Modulators of HEC1 activity and methods therefor
TWI640519B (zh) * 2011-11-29 2018-11-11 泰緯生命科技股份有限公司 Hec1活性調控因子及其調節方法
GB201820975D0 (en) * 2018-12-21 2019-02-06 Fund Calouste Gulbenkian Methods of cancer treatment

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1519736A2 (de) * 2002-06-12 2005-04-06 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. Verwendung von hec-1 antagonisten zur behandlung von proliferativen erkrankungen und krebs
US8252520B2 (en) 2002-10-11 2012-08-28 Taivex Therapeutics Corporation Methods and compounds for inhibiting Hec1 activity for the treatment of proliferative diseases
KR20060088537A (ko) 2003-09-06 2006-08-04 버텍스 파마슈티칼스 인코포레이티드 Atp-결합 카세트 수송체의 조절자
KR101357039B1 (ko) * 2004-12-08 2014-02-03 아벤티스 파마슈티칼스 인크. 도세탁셀에 대한 내성 또는 감수성을 측정하는 방법
WO2007004038A1 (en) 2005-07-05 2007-01-11 Pfizer Products Inc. Aminothiazole derivatives as agonists of the thrombopoietin receptor
KR100861278B1 (ko) * 2008-02-19 2008-10-01 고려대학교 산학협력단 암 치료용 리보핵산 의약 조성물
WO2009140621A2 (en) 2008-05-15 2009-11-19 Duke University Compositions and methods relating to heat shock transcription factor activating compounds and targets thereof
US8324385B2 (en) 2008-10-30 2012-12-04 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
EP2287197A1 (de) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET-Antikörper und seine Verwendung zur Erkennung und Diagnose von Krebs
EP2309273B1 (de) * 2009-09-16 2016-05-18 ZEILLINGER, Robert Neue Tumormarkiererbestimmung
CA2793311C (en) 2010-03-17 2019-01-15 Taivex Therapeutics Inc. Modulators of hec1 activity and methods therefor

Also Published As

Publication number Publication date
US9976183B2 (en) 2018-05-22
WO2013078145A1 (en) 2013-05-30
ES2736999T3 (es) 2020-01-09
TW201705987A (zh) 2017-02-16
JP2015500008A (ja) 2015-01-05
TWI641386B (zh) 2018-11-21
EP2783217A4 (de) 2015-05-27
TWI681055B (zh) 2020-01-01
TWI681054B (zh) 2020-01-01
JP6099662B2 (ja) 2017-03-22
US20130171634A1 (en) 2013-07-04
EP2783217B1 (de) 2019-04-24
SG11201402143YA (en) 2014-06-27
CN104395752B (zh) 2017-09-15
TW201706416A (zh) 2017-02-16
SG10201506881PA (en) 2015-10-29
CN104395752A (zh) 2015-03-04
MX2014006088A (es) 2015-04-08
TW201331371A (zh) 2013-08-01
EP2783217A1 (de) 2014-10-01

Similar Documents

Publication Publication Date Title
HK1216310A1 (zh) 脂質合成的雜環調節劑
ZA201502433B (en) Methods of host cell modification
HK1208445A1 (en) Heterocyclic modulators of lipid synthesis
IL228001A0 (en) Antibodies to 70cd
EP2771455A4 (de) Zelllinie zur produktion eines adenoassoziierten virus
EP2736919A4 (de) Neue 17-beta-heteroaryl-substituierte steroide als modulatoren der gabaa-rezeptoren
HK1204604A1 (en) Stereoselective total synthesis of noribogaine
EP2690442A4 (de) Marker zur bestimmung der empfindlichkeit gegen ein antikrebsmittel
HK1192323A1 (zh) -微管蛋白作為對呋咱並苯並咪唑類的藥物反應的生物標誌物的用途
GB201118302D0 (en) Improvements to tyres
EP2776586A4 (de) Biomarker der reaktion auf proteasomenhemmer
HK1189056A1 (zh) 作為藥物對呋咱並苯並咪唑響應的生物標記的用途
HK1203355A1 (en) Uses of 4-desferrithiocin analogs 4-
HK1202922A1 (en) Biomarkers for cancers responsive to modulators of hec1 activity hec1
EP2694705A4 (de) Mikrofabrikation von tunneln
GB2510539B (en) Biomarkers of cancer
EP2932272A4 (de) Shon als prognostischer biomarker für krebs und als prädiktor der reaktion auf eine endokrintherapie
EP2776043A4 (de) Biomarker der reaktion auf proteasomenhemmer
EP2809685A4 (de) Elektrochemische synthese von chlorchitosan
GB201201857D0 (en) Pseudonymisation/de-pseudonymisation of data
GB201118205D0 (en) Predictive biomarker for responsiveness to cancer agents